Pharmacological approaches to reperfusion therapy

Cardiovascular Research

Volumn 94, Issue 2, 2012, Pages 246-252

  Morel, Olivier ^a   Perret, Thibault ^b   Delarche, Nicolas ^c   Labque, Jean Noel ^d   Jouve, Bernard ^e   Elbaz, Meier ^f   Piot, Christophe ^g,h   Ovize, Michel ⁱ  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^c CENTRE HOSPITALIER DE PAU   (France)

^d Clinique Lafourcade   (France)

^e Service de Cardiologie   (France)

^f CHU RANGUEIL   (France)

^g INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^h HÔPITAL ARNAUD DE VILLENEUVE   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

Author keywords

Ischaemia; Myocardial infarction; Post conditioning; Reperfusion injury; ST elevation myocardial infarction

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ADENOSINE; CYCLOSPORIN A; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICORANDIL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEXELIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SODIUM PROTON EXCHANGE PROTEIN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PERFUSION; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC POSTCONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EMERGENCY MEDICAL SERVICES; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

EID: 84860112500     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs114     Document Type: Review

References (73)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-1248. (Pubitemid 27332143)
2. WijnsW, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-2555.
3. Anderson GF, Chu E. Expanding priorities-confronting chronic disease in countries with low income. N Engl J Med 2007;356:209-211. (Pubitemid 46143222)
4. Gelfand EV, Cannon CP. Myocardial infarction: contemporary management strategies. J Intern Med 2007;262:59-77. (Pubitemid 47000626)
5. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76:1713-1719. (Pubitemid 16196036)
6. Garcia-Dorado D, Barba I, Inserte J. Twenty-five years of preconditioning: are we ready for ischaemia? From coronary occlusion to systems biology and back. Cardiovasc Res 2011;91:378-381.
7. Garcia-Dorado D, Piper HM. Postconditioning: reperfusion of "reperfusion injury" after hibernation. Cardiovasc Res 2006;69:1-3.
8. Rodriguez-Sinovas A, García-Dorado D, Ruiz-Meana M, Soler-Soler J. Enhanced effect of gap junction uncouplers on macroscopic electrical properties of reperfused myocardium. J Physiol 2004;559:245-257. (Pubitemid 39206966)
9. Harper IS, Bond JM, Chacon E, Reece JM, Herman B, Lemasters JJ. Inhibition of Na +H+ exchange preserves viability, restores mechanical function, and prevents the pH paradox in reperfusion injury to rat neonatal myocytes. Basic Res Cardiol 1993;88: 430-442.
10. Inserte J, Garcia-Dorado D, Agulló L, Paniagua A, Soler-Soler J. Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 2000;45:351-359. (Pubitemid 30069500)
11. SchlackW, Uebing A, Schäfer M, Bier F, Schäfer S, Piper HM et al. Regional contractile blockade at the onset of reperfusion reduces infarct size in the dog heart. Pflugers Arch 1994;428:134-141. (Pubitemid 24238857)
12. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F,Wang NP, Guyton RA et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588. (Pubitemid 36885888)
13. Yang X-M, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004;44:1103-1110. (Pubitemid 39165147)
14. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005;111:194-197. (Pubitemid 40139731)
15. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95:230-232. (Pubitemid 39056282)
16. Argaud L, Prigent AF, Chalabreysse L, Loufouat J, Lagarde M, Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol 2004;286:H246-H251. (Pubitemid 38049486)
17. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovas Res 2002;55:534-543. (Pubitemid 34874948)
18. Argaud L, Gateau-Roesch O, Muntean D, Couture-Lepetit E, Loufouat J, Robert D et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005;38:367-374. (Pubitemid 40215206)
19. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011;109:1302-1308.
20. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62:74-85. (Pubitemid 38326813)
21. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011;14:893-907.
22. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
23. Heusch G. Postconditioning: old wine in a new bottle? J Am Coll Cardiol 2004;44: 1111-1112. (Pubitemid 39165148)
24. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010;105:771-785.
25. Cohen MV, Downey JM. Cardioprotection: spotlight on PKG. Br J Pharmacol 2007; 152:833-834. (Pubitemid 350100495)
26. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 2007;152:855-869. (Pubitemid 350100488)
27. Inserte J, Barba I, Hernando V, Abellán A, Ruiz-Meana M, Rodríguez-Sinovas A et al. Effect of acidic reperfusion on prolongation of intracellular acidosis and myocardial salvage. Cardiovasc Res 2008;77:782-790. (Pubitemid 351301862)
28. Inserte J, Barba I, Hernando V, Garcia-Dorado D. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. Cardiovasc Res 2009;81:116-122.
29. Rodríguez-Sinovas A, Cabestrero A, García del Blanco B, Inserte J, García A, García-Dorado D. Intracoronary acid infusion as an alternative to ischemic postconditioning in pigs. Basic Res Cardiol 2009;104:761-771.
30. López D, Rodríguez-Sinovas A, Agulló L, Inserte J, Cabestrero A, García-Dorado D. Acidic reoxygenation protects against endothelial dysfunction in rat aortic rings submitted to simulated ischemia. Am J Physiol Heart Circ Physiol 2008;295:H2409-H2416.
31. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I et al. Postconditioning the human heart. Circulation 2005;112:2143-2148. (Pubitemid 41475808)
32. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G et al. Long-term benefit of postconditioning. Circulation 2008;117:1037-1044.
33. Gibbons RJ, Valeti US, Aaroz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol 2004;44:1533-1542. (Pubitemid 39377707)
34. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334-341.
35. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51. (Pubitemid 17093191)
36. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106: 2351-2357. (Pubitemid 35244737)
37. Orn S, Manhenke C, Anand IS, Squire I, Nagel E, Edvardsen T et al. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol 2007;99:1109-1114. (Pubitemid 46560460)
38. Kelle S, Roes SD, Klein C, Kokocinski T, de Roos A, Fleck E et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 2009;54:1770-1777.
39. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-794. (Pubitemid 8235183)
40. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-644. (Pubitemid 9191795)
41. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ et al. Working Group of Cellular Biology of Heart of European Society of Cardiology. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010;87:406-423.
42. Gross ER, Gross GJ. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc Res 2006;70:212-221.
43. Chiari PC, Bienengraeber MW, Weihrauch D, Krolikowski JG, Kersten JR, Warltier DC et al. Role of endothelial nitric oxide synthase as a trigger and mediator of isoflurane-induced delayed preconditioning in rabbit myocardium. Anesthesiology 2005;103:74-83. (Pubitemid 40943139)
44. Piriou V, Chiari P, Gateau-Roesch O, Argaud L, Muntean D, Salles D. Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 2004;100:581-588. (Pubitemid 38268876)
45. Burley DS, Baxter GF. Pharmacological targets revealed by myocardial postconditioning. Curr Opin Pharmacol 2009;9:177-188.
46. Piot C, Croisille C, Staat P, Thibault H, Rioufol G, Mewton N et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359: 473-481.
47. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341:233-249. (Pubitemid 29373645)
48. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res 2004;61:372-385. (Pubitemid 38210145)
49. DiLisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 2001;276:2571-2575.
50. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-98.
51. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434:652-657.
52. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005;434:658-662. (Pubitemid 40488559)
53. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010;55:1200-1205.
54. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005;100:397-403. (Pubitemid 41300494)
55. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-141. (Pubitemid 43876097)
56. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009;104:1035-1040.
57. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011;147:124-131.
58. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH et al. HEBE investigators. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31:2593-2600.
59. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L et al. for the REVEAL Investigators. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A Randomized Controlled Trial. JAMA 2011;305: 1863-1872.
60. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51. (Pubitemid 46041725)
61. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG et al. COMMA Investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-1190. (Pubitemid 37099985)
62. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 1989;80:1388-1399. (Pubitemid 19282529)
63. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1-selective adenosine analogue protects the heart against infarction. Circulation 1992;85:659-665.
64. Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM et al. Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 2000;14:607-614. (Pubitemid 32217183)
65. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34: 1711-1720.
66. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G et al. AMP579 Delivery for Myocardial Infarction REduction study. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 2003;146:146-152. (Pubitemid 36851314)
67. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C et al. Highdose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011;32:867-877.
68. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54: 146-151. (Pubitemid 40105106)
69. Treiman M, Elvekjaer M, Engstrøm T, Jensen JS. Glucagon-like peptide 1-a cardiologic dimension. Trends Cardiovasc Med 2010;20:8-12.
70. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-249.
71. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
72. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008;117:2340-2350. (Pubitemid 351653542)
73. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2011; doi:10.1093/eurheartj/ehr309.